The phrase "assessed at primary" is correct and usable in written English.
It can be used in contexts related to evaluations or measurements that occur at a primary level, such as in education or assessments.
Example: "The students' skills were assessed at primary to determine their readiness for advanced coursework."
Alternatives: "evaluated at primary" or "measured at primary level".
In the present study, we assessed the implementation of PO as a triage tool for young infants assessed at primary care clinics in Karachi, Pakistan.
In case of impossibility to proceed to primary optimal cytoreduction, as assessed at primary laparotomic effort, patients were triaged to neoadjuvant chemotherapy (Fanfani et al, 2003; Vergote et al, 2005).
Response to treatment will be assessed at primary and metastatic sites using the Response Evaluation Criteria In Solid Tumors (RECIST) by computed tomography (CT) imaging before treatment initiation and after exposure to the therapeutic agent before patients undergo nephrectomy.
The increase in workload is caused by government policy innovations, including significant changes to how pupil progress is assessed at both primary and secondary level – a programme that has been "far too hastily implemented", says Bousted.
Changes to factors such as sleeplessness, energy loss from within the BDI II could not be assessed at the primary outcome point.
The clinical condition of each patient was assessed at the primary care center by his/her general practitioner on the day of inclusion in the study (baseline assessment, day 1) and 15 and 60 days later.
This was a preliminary randomised, single blind controlled trial, with two parallel arms, assessed at 12 weeks (primary time-point for research question 1) and 18 weeks after baseline (primary time-point for research question 2).
Reduction in 24-hour ambulatory systolic blood pressure will be assessed at 3 months (primary end point).
Efficacy assessed at week 12 (primary endpoint) revealed ACR 20 scores for the active treatment group of 42% (32 of 76), as compared with 14% (10 of 70) in the control group (P = 0.0002).
Efficacy assessed at week 12 (primary endpoint) revealed statistically significant PASI 75 scores for all groups, achieving 52% (45 mg × 1), 59%9090 mg × 1), 67% (45 mg × 4) and 81%9090 mg × 4) in the ustekinumab group, as compared with 2% in the control group.
Outcomes are assessed at baseline, 12 weeks (primary time point), and 36 weeks (to assess maintenance of treatment effects).
